KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBT (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EBT for 15 consecutive years, with -$21.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 65.09% year-over-year to -$21.1 million, compared with a TTM value of -$49.3 million through Dec 2025, up 84.63%, and an annual FY2025 reading of -$49.3 million, up 84.63% over the prior year.
  • EBT was -$21.1 million for Q4 2025 at Travere Therapeutics, down from $25.7 million in the prior quarter.
  • Across five years, EBT topped out at $25.7 million in Q3 2025 and bottomed at -$135.8 million in Q1 2024.
  • Average EBT over 5 years is -$64.7 million, with a median of -$74.8 million recorded in 2022.
  • The sharpest move saw EBT plummeted 194.77% in 2021, then surged 146.89% in 2025.
  • Year by year, EBT stood at -$88.8 million in 2021, then increased by 3.6% to -$85.6 million in 2022, then fell by 3.45% to -$88.5 million in 2023, then surged by 31.84% to -$60.3 million in 2024, then skyrocketed by 65.09% to -$21.1 million in 2025.
  • Business Quant data shows EBT for TVTX at -$21.1 million in Q4 2025, $25.7 million in Q3 2025, and -$12.7 million in Q2 2025.